This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
serum samples | 737 |
mg kg | 667 |
extracellular vesicles | 599 |
summary conclusion | 561 |
immune response | 537 |
ng ml | 531 |
cell lines | 525 |
western blot | 511 |
influenza virus | 507 |
control group | 493 |
flow cytometry | 467 |
present study | 462 |
gene expression | 461 |
significantly higher | 443 |
pg ml | 419 |
blood samples | 356 |
mg ml | 352 |
bone marrow | 348 |
cell line | 339 |
amino acid | 335 |
peripheral blood | 332 |
influenza viruses | 311 |
cd cd | 309 |
linked immunosorbent | 297 |
immunosorbent assay | 287 |
statistically significant | 280 |
specific ige | 273 |
results suggest | 272 |
performed using | 272 |
whole blood | 272 |
significant difference | 269 |
monoclonal antibodies | 265 |
respiratory syndrome | 260 |
cancer cells | 258 |
breast cancer | 258 |
important role | 257 |
significant differences | 257 |
acute respiratory | 255 |
endothelial cells | 254 |
electron microscopy | 253 |
immune responses | 253 |
allergic rhinitis | 251 |
immune system | 251 |
cell culture | 248 |
clinical signs | 241 |
mrna expression | 236 |
time pcr | 235 |
mg dl | 232 |
significantly increased | 230 |
oxidative stress | 230 |
cell proliferation | 228 |
pandemic influenza | 226 |
protein expression | 221 |
inflammatory response | 215 |
monoclonal antibody | 213 |
severe acute | 211 |
specific antibodies | 210 |
antibody responses | 208 |
porcine epidemic | 207 |
seasonal influenza | 206 |
indirect elisa | 206 |
public health | 203 |
western blotting | 198 |
infected cells | 198 |
years old | 197 |
antibody response | 197 |
room temperature | 197 |
cell surface | 197 |
stem cells | 197 |
significantly reduced | 196 |
mean age | 192 |
mass spectrometry | 192 |
significantly lower | 189 |
epithelial cells | 189 |
risk factors | 188 |
commercially available | 186 |
virus infection | 186 |
dependent manner | 185 |
data suggest | 184 |
results indicate | 178 |
epidemic diarrhea | 176 |
molecular weight | 173 |
nitric oxide | 171 |
previously described | 171 |
respiratory tract | 171 |
pregnant women | 170 |
results showed | 170 |
smooth muscle | 170 |
body weight | 169 |
significant increase | 168 |
type i | 168 |
cancer cell | 167 |
cell death | 166 |
blood pressure | 166 |
two groups | 165 |
growth factor | 164 |
stem cell | 163 |
dendritic cells | 163 |
spike protein | 162 |
healthy controls | 162 |
first time | 162 |
high levels | 162 |
infectious diseases | 160 |
avian influenza | 159 |
nucleic acid | 159 |
wild type | 157 |
nucleocapsid protein | 157 |
neutralizing antibodies | 156 |
statistical analysis | 155 |
antibody titers | 155 |
serological assays | 154 |
hong kong | 154 |
united states | 153 |
chain reaction | 153 |
amino acids | 153 |
positive results | 152 |
food allergy | 152 |
cell types | 150 |
cell activation | 150 |
negative control | 150 |
diarrhea virus | 150 |
skin prick | 148 |
cytokine production | 147 |
cell cycle | 147 |
elisa kit | 146 |
derived evs | 146 |
blot analysis | 145 |
polymerase chain | 145 |
cord uid | 143 |
doc id | 143 |
significantly different | 142 |
mast cells | 142 |
serum levels | 142 |
escherichia coli | 142 |
septic shock | 141 |
three times | 141 |
inflammatory cytokines | 140 |
real time | 140 |
nanoparticle tracking | 139 |
prostate cancer | 138 |
determine whether | 138 |
lateral flow | 138 |
igg antibodies | 136 |
tracking analysis | 135 |
class i | 134 |
side effects | 134 |
lg ml | 133 |
widely used | 133 |
mrna levels | 132 |
necrosis factor | 132 |
expression levels | 131 |
lymph nodes | 131 |
author funder | 130 |
granted medrxiv | 130 |
transmissible gastroenteritis | 128 |
significantly decreased | 127 |
cancer patients | 127 |
plasma samples | 127 |
gestational age | 126 |
determined using | 126 |
time points | 125 |
cell responses | 124 |
recombinant protein | 124 |
mouse model | 124 |
samples collected | 123 |
analysis revealed | 122 |
risk factor | 122 |
acute phase | 121 |
days post | 121 |
cd cells | 120 |
clinical trials | 120 |
mononuclear cells | 120 |
measured using | 119 |
copyright holder | 118 |
positive samples | 118 |
may contribute | 118 |
pcr assay | 117 |
differentially expressed | 117 |
may play | 116 |
previous studies | 116 |
findings suggest | 115 |
results obtained | 115 |
specific antibody | 115 |
results show | 115 |
atopic dermatitis | 115 |
surface plasmon | 114 |
tumor necrosis | 114 |
goat anti | 114 |
staphylococcus aureus | 114 |
analyzed using | 113 |
positive control | 113 |
gel electrophoresis | 113 |
elisa method | 112 |
ebola virus | 112 |
culture medium | 112 |
case report | 111 |
version posted | 111 |
transcription factor | 111 |
grass pollen | 110 |
blood flow | 110 |
cell viability | 110 |
median age | 110 |
immune cells | 109 |
specific igg | 109 |
innate immune | 109 |
fold increase | 109 |
commonly used | 109 |
protein levels | 109 |
plasmon resonance | 108 |
current study | 108 |
logistic regression | 107 |
syndrome coronavirus | 107 |
university hospital | 107 |
mast cell | 106 |
healthy volunteers | 106 |
previously reported | 106 |
least one | 104 |
predictive value | 104 |
exclusion chromatography | 103 |
molecular mechanisms | 102 |
patients treated | 102 |
two different | 101 |
analysis showed | 101 |
adhesion molecules | 101 |
organ failure | 100 |
test results | 100 |
may also | 100 |
plasma levels | 100 |
type ii | 100 |
three different | 100 |
human serum | 100 |
influenza vaccine | 99 |
fecal samples | 99 |
ex vivo | 99 |
time rt | 99 |
medical center | 99 |
structural proteins | 99 |
blood donors | 98 |
informed consent | 98 |
fcov type | 98 |
neutralizing antibody | 97 |
total ige | 97 |
endothelial cell | 97 |
year old | 96 |
nervous system | 96 |
taken together | 96 |
bovine serum | 95 |
nkt cells | 95 |
animal models | 95 |
extracellular matrix | 94 |
capillary electrophoresis | 94 |
virus isolation | 94 |
cell cultures | 93 |
transmission electron | 93 |
based elisa | 93 |
recent studies | 93 |
results demonstrate | 93 |
care workers | 92 |
allergic patients | 92 |
adverse events | 92 |
insulin resistance | 92 |
also observed | 92 |
nk cells | 92 |
wound healing | 91 |
optical density | 91 |
infectious bronchitis | 91 |
derived exosomes | 91 |
novel coronavirus | 90 |
total rna | 90 |
well plates | 90 |
specific cd | 90 |
deficient mice | 90 |
weight loss | 90 |
may provide | 89 |
increased risk | 89 |
higher levels | 89 |
gastroenteritis virus | 89 |
statistical significance | 89 |
sandwich elisa | 89 |
mesenchymal stem | 89 |
signal transduction | 88 |
culture media | 88 |
vip aa | 88 |
elisa using | 87 |
iu ml | 87 |
clinical samples | 87 |
may lead | 87 |
binding protein | 87 |
plasma membrane | 87 |
lung cancer | 87 |
viral infections | 87 |
wide range | 87 |
significant reduction | 87 |
sequence analysis | 87 |
inflammatory mediators | 86 |
disease severity | 86 |
igg antibody | 86 |
total protein | 86 |
healthy individuals | 86 |
house dust | 85 |
three groups | 85 |
proinflammatory cytokines | 85 |
tissue culture | 85 |
negative controls | 84 |
rheumatoid arthritis | 84 |
tumor cells | 84 |
capture elisa | 84 |
intensive care | 84 |
control groups | 84 |
experimentally infected | 83 |
one patient | 83 |
secondary antibody | 83 |
plasma cells | 83 |
peer review | 83 |
data indicate | 83 |
high sensitivity | 83 |
size exclusion | 83 |
th cells | 83 |
mhc class | 83 |
blood cells | 82 |
growth factors | 82 |
reactive oxygen | 82 |
sars coronavirus | 82 |
infectious disease | 82 |
prick test | 82 |
closely related | 82 |
extracellular vesicle | 82 |
positive correlation | 82 |
made available | 82 |
usa introduction | 82 |
ige levels | 81 |
also found | 81 |
prick tests | 81 |
viral rna | 81 |
healthy subjects | 81 |
recombinant proteins | 81 |
data show | 81 |
ovarian cancer | 81 |
healthy donors | 81 |
long term | 81 |
nucleic acids | 80 |
age groups | 80 |
united kingdom | 80 |
od values | 80 |
positive sera | 79 |
dna damage | 79 |
increased expression | 79 |
first trimester | 79 |
elisa kits | 79 |
serum albumin | 79 |
elisa test | 78 |
transcription factors | 78 |
inhibitory effect | 78 |
reactive protein | 78 |
dust mite | 78 |
regression analysis | 78 |
antibody levels | 78 |
protective effect | 77 |
serological tests | 77 |
significant decrease | 77 |
antibody titer | 77 |
inflammatory responses | 77 |
antibody detection | 77 |
diagnostic tests | 76 |
amniotic fluid | 76 |
inflammatory diseases | 76 |
study group | 76 |
bronchitis virus | 76 |
reverse transcription | 76 |
international license | 76 |
study design | 75 |
density gradient | 75 |
study period | 75 |
fetal growth | 74 |
platelet activation | 74 |
blood mononuclear | 74 |
health care | 74 |
serum sample | 74 |
positive serum | 74 |
igg elisa | 73 |
clinical trial | 73 |
experimental infection | 73 |
fusion protein | 73 |
neutralization assay | 73 |
elisa assay | 73 |
infected mice | 73 |
viral load | 73 |
per well | 73 |
time point | 73 |
similar results | 73 |
clinical symptoms | 73 |
virus replication | 72 |
expression level | 72 |
platelet aggregation | 72 |
heart rate | 72 |
gold standard | 72 |
mdck cells | 72 |
signaling pathways | 72 |
body mass | 71 |
skeletal muscle | 71 |
allergic reactions | 71 |
blocking elisa | 71 |
high level | 71 |
oxygen species | 71 |
kg day | 70 |
significant correlation | 70 |
autoimmune diseases | 70 |
data demonstrate | 70 |
dose dependent | 70 |
cov infection | 70 |
patients received | 70 |
previously shown | 70 |
derived extracellular | 70 |
muscle cells | 70 |
swine influenza | 69 |
umbilical cord | 69 |
within hours | 69 |
surface markers | 69 |
phage display | 69 |
tested positive | 69 |
receptor binding | 69 |
recipient cells | 69 |
fatty acids | 69 |
key role | 69 |
tract infections | 68 |
detection limit | 68 |
viral infection | 68 |
standard deviation | 68 |
early detection | 68 |
septic patients | 68 |
well tolerated | 68 |
high affinity | 68 |
significantly associated | 68 |
evaluated using | 68 |
highly sensitive | 68 |
preliminary results | 68 |
colorectal cancer | 68 |
liquid chromatography | 68 |
spinal cord | 68 |
study showed | 67 |
respiratory syncytial | 67 |
skin test | 67 |
egg yolk | 67 |
commercial elisa | 67 |
severe disease | 67 |
airway inflammation | 67 |
treated mice | 67 |
infected animals | 66 |
buffered saline | 66 |
increased levels | 66 |
protein kinase | 66 |
using elisa | 66 |
central nervous | 66 |
treatment groups | 66 |
serological assay | 66 |
diabetes mellitus | 66 |
early diagnosis | 66 |
human influenza | 66 |
heart failure | 65 |
control subjects | 65 |
multiple organ | 65 |
type diabetes | 65 |
elisa plates | 65 |
serial dilutions | 65 |
disease control | 65 |
class ii | 65 |
disease virus | 65 |
acid sequence | 65 |
ob gyn | 64 |
target cells | 64 |
control animals | 64 |
phylogenetic analysis | 64 |
faecal samples | 64 |
high risk | 64 |
clinical practice | 64 |
red blood | 64 |
urinary tract | 64 |
physical examination | 64 |
human plasma | 64 |
patients without | 63 |
elisa results | 63 |
even though | 63 |
fatty acid | 63 |
colloidal gold | 63 |
large number | 63 |
low levels | 63 |
group i | 63 |
influenza pandemic | 63 |
cutoff value | 63 |
platelet count | 63 |
liquid biopsy | 63 |
clinical isolates | 63 |
respiratory disease | 63 |
activated protein | 63 |
health organization | 63 |
flow serological | 63 |
world health | 63 |
affinity chromatography | 63 |
molecular biology | 63 |
old female | 63 |
virus strains | 62 |
highly pathogenic | 62 |
conditioned media | 62 |
new york | 62 |
preliminary data | 62 |
medrxiv preprint | 62 |
treatment group | 62 |
higher sensitivity | 62 |
stromal cells | 62 |
potential role | 62 |
crucial role | 62 |
mortality rate | 62 |
expression vector | 62 |
false positive | 62 |
skin tests | 62 |
old male | 62 |
natural killer | 62 |
hepatitis virus | 61 |
detect antibodies | 61 |
sars patients | 61 |
diagnostic methods | 61 |
cell receptor | 61 |
poorly understood | 61 |
cells expressing | 61 |
coronavirus disease | 61 |
prospective study | 61 |
confocal microscopy | 61 |
critical role | 61 |
influenza infection | 61 |
syncytial virus | 61 |
highly conserved | 61 |
surfactant protein | 61 |
ko mice | 60 |
family members | 60 |
rapid detection | 60 |
biological activity | 60 |
also used | 60 |
tgev prcv | 60 |
upper respiratory | 60 |
low dose | 60 |
negative sera | 60 |
skin testing | 60 |
negative results | 60 |
described previously | 60 |
cell adhesion | 60 |
fold higher | 60 |
naturally infected | 60 |
elisa assays | 59 |
genomic dna | 59 |
middle east | 59 |
horseradish peroxidase | 59 |
binding domain | 59 |
preterm birth | 59 |
two weeks | 59 |
receptor antagonist | 59 |
enzyme activity | 59 |
sars cov | 59 |
high dose | 59 |
serum concentrations | 59 |
surface expression | 59 |
cell lysates | 58 |
specific primers | 58 |
samples obtained | 58 |
small rna | 58 |
plasma concentrations | 58 |
ms ms | 58 |
one year | 58 |
cohort study | 58 |
patients undergoing | 58 |
cd expression | 58 |
quality control | 58 |
positive cells | 58 |
study aimed | 58 |
control antigen | 58 |
myocardial infarction | 58 |
serum antibody | 58 |
also tested | 57 |
primary care | 57 |
multiple sclerosis | 57 |
treated patients | 57 |
negative serum | 57 |
virus neutralization | 57 |
bl mice | 57 |
clinically relevant | 57 |
assessed using | 57 |
allergic asthma | 57 |
cell type | 57 |
lung injury | 57 |
research institute | 57 |
adaptive immune | 57 |
naturally occurring | 57 |
luminex assay | 57 |
ev isolation | 57 |
apoptotic cells | 57 |
family history | 56 |
studies showed | 56 |
lipid peroxidation | 56 |
od value | 56 |
recent years | 56 |
humoral immune | 56 |
assay using | 56 |
two patients | 56 |
high specificity | 56 |
inkt cells | 56 |
total number | 56 |
asthma symptoms | 56 |
healthy dogs | 56 |
bronchoalveolar lavage | 56 |
venous blood | 56 |
calculated using | 56 |
university medical | 56 |
isolated using | 56 |
pbs containing | 56 |
mouth disease | 55 |
severe asthma | 55 |
analysis using | 55 |
times higher | 55 |
animal model | 55 |
normal range | 55 |
human coronavirus | 55 |
future studies | 55 |
treated cells | 55 |
critically ill | 55 |
clinical studies | 55 |
disease activity | 55 |
pilot study | 55 |
inflammatory bowel | 55 |
confidence interval | 55 |
cell response | 55 |
innate immunity | 55 |
cell growth | 55 |
menstrual cycle | 55 |
washed three | 55 |
cord blood | 55 |
clinical disease | 54 |
healthy control | 54 |
lung function | 54 |
major role | 54 |
sample size | 54 |
cell function | 54 |
protein content | 54 |
igm antibodies | 54 |
asthma control | 54 |
symptom onset | 54 |
bacterial infections | 54 |
cells treated | 54 |
convalescent plasma | 54 |
viruses isolated | 54 |
low molecular | 54 |
size distribution | 54 |
respiratory symptoms | 54 |
ml min | 54 |
significantly greater | 54 |
vero cells | 54 |
hours post | 54 |
guinea pig | 54 |
culture supernatants | 53 |
also showed | 53 |
increased significantly | 53 |
conditioned medium | 53 |
positive predictive | 53 |
viral replication | 53 |
polyacrylamide gel | 53 |
drug resistance | 53 |
diagnostic accuracy | 53 |
tumour cells | 53 |
patients receiving | 53 |
chronic inflammatory | 53 |
lymph node | 53 |
control mice | 53 |
lower respiratory | 53 |
therapeutic potential | 53 |
type mice | 53 |
elevated levels | 53 |
antigen presentation | 53 |
cytopathic effect | 53 |
trophoblast cells | 53 |
analysed using | 52 |
significantly elevated | 52 |
may result | 52 |
bacterial infection | 52 |
serially diluted | 52 |
viral antigen | 52 |
pseudomonas aeruginosa | 52 |
elisa system | 52 |
care unit | 52 |
inflammatory cytokine | 52 |
considered positive | 52 |
diagnostic performance | 52 |
strains isolated | 52 |
considered significant | 52 |
nasal spray | 52 |
serum dilution | 52 |
placebo group | 52 |
transgenic mice | 52 |
general population | 52 |
one hour | 52 |
allergic diseases | 52 |
blood cell | 52 |
age group | 52 |
different types | 52 |
viral proteins | 52 |
resistant strains | 52 |
early stage | 52 |
patients suffering | 52 |
immunofluorescence assay | 51 |
reverse transcriptase | 51 |
cells showed | 51 |
preterm delivery | 51 |
group compared | 51 |
factor viii | 51 |
treated animals | 51 |
serum antibodies | 51 |
may represent | 51 |
respiratory distress | 51 |
signaling pathway | 51 |
showed significant | 51 |
porcine respiratory | 51 |
infected patients | 51 |
ultrasensitive elisa | 51 |
east respiratory | 51 |
neutralization test | 51 |
negative samples | 51 |
influenza vaccines | 50 |
mycobacterium tuberculosis | 50 |
urine samples | 50 |
respiratory coronavirus | 50 |
protective immunity | 50 |
time course | 50 |
rights reserved | 50 |
leaf curl | 50 |
protein level | 50 |
clinical chemistry | 50 |
cerebrospinal fluid | 50 |
blood glucose | 50 |
hydrogen peroxide | 50 |
polyclonal antibodies | 50 |
vg vd | 50 |
weight gain | 50 |
flow cytometric | 50 |
mouse igg | 50 |
results indicated | 50 |
presenting cells | 50 |
high prevalence | 49 |
bronchial asthma | 49 |
full length | 49 |
compared using | 49 |
three patients | 49 |
growth restriction | 49 |
thermo fisher | 49 |
binding sites | 49 |
also significantly | 49 |
preterm labor | 49 |
mass index | 49 |
mouse hepatitis | 48 |
tnf production | 48 |
one hundred | 48 |
primary human | 48 |
guinea pigs | 48 |
antibiotic therapy | 48 |
cell migration | 48 |
protein synthesis | 48 |
differential ultracentrifugation | 48 |
laboratory mice | 48 |
quantitative rt | 48 |
detected using | 48 |
antigen presenting | 48 |
like particles | 48 |
clinical diagnosis | 48 |
intercellular communication | 48 |
blood plasma | 48 |
blood cultures | 48 |
hospitalized patients | 48 |
healthcare workers | 48 |
last years | 48 |
cellular immune | 48 |
days later | 48 |
patients compared | 47 |
autoimmune disease | 47 |
alkaline phosphatase | 47 |
also performed | 47 |
one week | 47 |
abdominal pain | 47 |
low concentrations | 47 |
phage clones | 47 |
clinical data | 47 |
well known | 47 |
obtained using | 47 |
survival rate | 47 |
small extracellular | 47 |
differential expression | 47 |
study demonstrates | 47 |
sample collection | 47 |
previous study | 47 |
cell count | 47 |
medical records | 47 |
respiratory viruses | 47 |
highly purified | 47 |
blood culture | 47 |
mechanisms underlying | 47 |
epidemiological studies | 47 |
mm nacl | 47 |
food allergens | 47 |
ca i | 47 |
final concentration | 47 |
also known | 46 |
host response | 46 |
ns protein | 46 |
based assay | 46 |
viral antigens | 46 |
tested using | 46 |
different concentrations | 46 |
like receptors | 46 |
protein concentration | 46 |
infectious agents | 46 |
randomly selected | 46 |
performed according | 46 |
western blots | 46 |
investigate whether | 46 |
within minutes | 46 |
specific igy | 46 |
high concentrations | 46 |
enzyme immunoassay | 46 |
six months | 46 |
birth weight | 46 |
may cause | 46 |
central role | 46 |
better understanding | 46 |
using flow | 46 |
human myometrium | 46 |
clinical course | 46 |
retrospective study | 46 |
national institute | 46 |
day post | 46 |
adipose tissue | 46 |
healthy blood | 45 |
study included | 45 |
vp protein | 45 |
lymphocytic choriomeningitis | 45 |
patients showed | 45 |
north america | 45 |
isolation methods | 45 |
cells using | 45 |
elisa tests | 45 |
control cells | 45 |
dna vaccine | 45 |
apoptotic cell | 45 |
study population | 45 |
persistent asthma | 45 |
significant changes | 45 |
cytokine levels | 45 |
host defense | 45 |
pregnant rats | 45 |
significant association | 45 |
expression system | 45 |
dawley rats | 45 |
wistar rats | 45 |
cell membrane | 45 |
vascular endothelial | 45 |
connective tissue | 45 |
detection antibody | 45 |
tissue factor | 45 |
virus antigen | 45 |
induced apoptosis | 45 |
viral shedding | 45 |
ic values | 44 |
tyrosine kinase | 44 |
fluorescence microscopy | 44 |
data analysis | 44 |
uric acid | 44 |
blood loss | 44 |
igg levels | 44 |
first study | 44 |
high degree | 44 |
signalling pathways | 44 |
results demonstrated | 44 |
receptor expression | 44 |
isolated evs | 44 |
single nucleotide | 44 |
vaccine strain | 44 |
respiratory infections | 44 |
like receptor | 44 |
binding site | 44 |
pivotal role | 44 |
ev markers | 44 |
human blood | 44 |
inflammatory cells | 44 |
stranded rna | 44 |
way anova | 44 |
study shows | 44 |
using different | 44 |
several studies | 44 |
adhesion molecule | 44 |
cell population | 44 |
diagnostic test | 44 |
positive result | 44 |
also evaluated | 44 |
single dose | 44 |
apc resistance | 44 |
fisher scientific | 44 |
food allergies | 44 |
inhibitory effects | 44 |
bowel disease | 44 |
may occur | 44 |
superoxide dismutase | 44 |
evs derived | 44 |
cell differentiation | 44 |
data suggests | 43 |
investigated whether | 43 |
ae log | 43 |
organ dysfunction | 43 |
marburg virus | 43 |
systemic inflammatory | 43 |
newly developed | 43 |
heart disease | 43 |
also increased | 43 |
mouse ifn | 43 |
studies suggest | 43 |
levels increased | 43 |
two hours | 43 |
normal human | 43 |
weeks gestation | 43 |
membrane protein | 43 |
detection methods | 43 |
proteomic analysis | 43 |
four different | 43 |
human umbilical | 43 |
arachidonic acid | 43 |
using two | 43 |
nasal congestion | 43 |
ev cargo | 43 |
functional assays | 42 |
correlation coefficient | 42 |
free radical | 42 |
may affect | 42 |
human igg | 42 |
capture antibody | 42 |
acute pancreatitis | 42 |
control samples | 42 |
iga elisa | 42 |
genes encoding | 42 |
cell development | 42 |
pcr assays | 42 |
patient sera | 42 |
causative agent | 42 |
differential diagnosis | 42 |
disease progression | 42 |
exact test | 42 |
serum ige | 42 |
arterial blood | 42 |
adverse reactions | 42 |
mg bid | 42 |
high throughput | 42 |
chronic disease | 42 |
cell populations | 42 |
negative correlation | 42 |
clinical specimens | 42 |
hemorrhagic shock | 42 |
lung tissue | 42 |
mouse models | 42 |
fetal membranes | 42 |
potential use | 42 |
human sera | 42 |
specific iga | 42 |
within days | 42 |
epithelial cell | 42 |
viral particles | 42 |
differential centrifugation | 42 |
umbilical vein | 42 |
peanut allergy | 42 |
may explain | 41 |
ug ml | 41 |
specific binding | 41 |
cesarean section | 41 |
studies will | 41 |
first step | 41 |
fusion proteins | 41 |
host immune | 41 |
vaccine development | 41 |
significantly inhibited | 41 |
tissue damage | 41 |
cell subsets | 41 |
producing cells | 41 |
immunochromatographic strip | 41 |
children aged | 41 |
state university | 41 |
tissue samples | 41 |
ev release | 41 |
i molecules | 41 |
adverse effects | 41 |
high mortality | 41 |
virus infections | 41 |
clostridium difficile | 41 |
significantly improved | 41 |
pathogenic avian | 41 |
negative predictive | 41 |
beneficial effects | 40 |
gene segments | 40 |
lactate dehydrogenase | 40 |
murine model | 40 |
diagnostic sensitivity | 40 |
highly specific | 40 |
currently available | 40 |
host cells | 40 |
relatively high | 40 |
chronic urticaria | 40 |
phase i | 40 |
blood count | 40 |
brain tissue | 40 |
conducted using | 40 |
culture supernatant | 40 |
genes involved | 40 |
based elisas | 40 |
nuclear factor | 40 |
reperfusion injury | 40 |
systemic lupus | 40 |
asthmatic patients | 40 |
control serum | 40 |
direct contact | 40 |
oxide synthase | 40 |
leading cause | 40 |
house elisa | 40 |
surface area | 40 |
linear regression | 40 |
new therapeutic | 40 |
associated coronavirus | 40 |
induced thrombocytopenia | 40 |
tumor cell | 39 |
tested negative | 39 |
using specific | 39 |
adaptive immunity | 39 |
quantified using | 39 |
chicken eggs | 39 |
may help | 39 |
positive skin | 39 |
data obtained | 39 |
ige level | 39 |
antibody titres | 39 |
cleavage site | 39 |
decreased significantly | 39 |
antigen capture | 39 |
different doses | 39 |
recombinant nucleocapsid | 39 |
pcr analysis | 39 |
diabetic patients | 39 |
mechanisms involved | 39 |
pcr positive | 39 |
lupus erythematosus | 39 |
acid residues | 39 |
frequently used | 39 |
specific siga | 39 |
fat diet | 39 |
renal failure | 39 |
specific immune | 39 |
multiplex pcr | 39 |
will help | 39 |
effective treatment | 39 |
evs isolated | 39 |
present work | 39 |
large scale | 39 |
identified using | 39 |
different cell | 39 |
heat shock | 39 |
tumor growth | 39 |
virus isolates | 39 |
first wave | 39 |
three days | 39 |
cell survival | 39 |
possible role | 39 |
immune cell | 39 |
streptococcus pneumoniae | 39 |
antibody testing | 38 |
statistical analyses | 38 |
group ii | 38 |
potential therapeutic | 38 |
rapid diagnosis | 38 |
circulating levels | 38 |
peritoneal macrophages | 38 |
rat model | 38 |
particle size | 38 |
university school | 38 |
using standard | 38 |
infected dogs | 38 |
inclusion criteria | 38 |
gram negative | 38 |
folic acid | 38 |
allergic reaction | 38 |
see table | 38 |
choriomeningitis virus | 38 |
much higher | 38 |
ill patients | 38 |
expression pattern | 38 |
viral diseases | 38 |
higher risk | 38 |
remains unclear | 38 |
absorbance values | 38 |
sle patients | 38 |
chronic inflammation | 38 |
different time | 38 |
pcr amplification | 38 |
animal health | 38 |
better understand | 38 |
low level | 38 |
small number | 38 |
pcr using | 38 |
infected individuals | 38 |
cfu ml | 38 |
human ifn | 38 |
progenitor cells | 38 |
antimicrobial resistance | 38 |
mg day | 38 |
total antibody | 38 |
factors associated | 38 |
renal function | 38 |
skin lesions | 38 |
infected pigs | 37 |
recombinant human | 37 |
rabbit anti | 37 |
human lung | 37 |
control study | 37 |
wt mice | 37 |
study suggests | 37 |
expression profiles | 37 |
old woman | 37 |
written informed | 37 |
may serve | 37 |
expression profile | 37 |
promoter activity | 37 |
antimicrobial activity | 37 |
outer membrane | 37 |
purified using | 37 |
two methods | 37 |
laboratory tests | 37 |
target genes | 37 |
pdm virus | 37 |
growth hormone | 37 |
serological testing | 37 |
cells may | 37 |
based assays | 37 |
birch pollen | 37 |
applied biosystems | 37 |
evs released | 37 |
per day | 37 |
human monocytes | 37 |
human cells | 37 |
false positives | 37 |
posted september | 37 |
endoplasmic reticulum | 37 |
medical school | 37 |
vascular smooth | 37 |
animal species | 37 |
conjugated goat | 37 |
common cause | 37 |
influenza surveillance | 37 |
cardiovascular disease | 37 |
milk allergy | 37 |
pandemic virus | 37 |
year period | 37 |
showed higher | 37 |
distress syndrome | 37 |
polyclonal antibody | 37 |
positive elisa | 37 |
elisa based | 37 |
hypersensitivity reactions | 37 |
broad spectrum | 37 |
antibody tests | 37 |
function tests | 37 |
pulmonary disease | 37 |
free ultrasensitive | 36 |
first report | 36 |
nk cell | 36 |
diagnostic assays | 36 |
cervical ripening | 36 |
tract infection | 36 |
hla class | 36 |
diagnostic tool | 36 |
drug delivery | 36 |
cells compared | 36 |
findings indicate | 36 |
showed high | 36 |
ethics committee | 36 |
significantly less | 36 |
available elisa | 36 |
cystic fibrosis | 36 |
scid mice | 36 |
coronavirus spike | 36 |
inflammatory processes | 36 |
influenza vaccination | 36 |
positively correlated | 36 |
veterinary medicine | 36 |
cell communication | 36 |
european countries | 36 |
situ hybridization | 36 |
relatively low | 36 |
converting enzyme | 36 |
pulmonary hypertension | 36 |
well plate | 36 |
positive test | 36 |
four patients | 36 |
like viruses | 36 |
virus ns | 36 |
also determined | 36 |
clinical use | 36 |
live attenuated | 36 |
biologically active | 36 |
dna sequencing | 36 |
immunosorbent assays | 36 |
control sera | 35 |
simultaneous detection | 35 |
significant improvement | 35 |
free radicals | 35 |
antibiotic treatment | 35 |
ge healthcare | 35 |
white blood | 35 |
data support | 35 |
breast milk | 35 |
significant role | 35 |
pcr products | 35 |
women undergoing | 35 |
provocation test | 35 |
significantly correlated | 35 |
barr virus | 35 |
related genes | 35 |
laboratory testing | 35 |
significant effect | 35 |
disease onset | 35 |
binding proteins | 35 |
binding affinity | 35 |
assay results | 35 |
high incidence | 35 |
indirect elisas | 35 |
average age | 35 |
tissue injury | 35 |
rapid test | 35 |
structural protein | 35 |
quantitative real | 35 |
positive reactions | 35 |
phase ii | 35 |
two years | 35 |
induced arthritis | 35 |
specific immunotherapy | 35 |
poor prognosis | 35 |
gradient centrifugation | 35 |
previously demonstrated | 35 |
data showed | 35 |
immunized mice | 35 |
mm tris | 35 |
coronavirus infection | 35 |
well established | 35 |
also demonstrated | 35 |
human peripheral | 35 |
authors declare | 35 |
lower levels | 35 |
antibody production | 35 |
bile acid | 34 |
virus strain | 34 |
biochemical parameters | 34 |
sequence homology | 34 |
cell wall | 34 |
glucose tolerance | 34 |
vaccinated animals | 34 |
good correlation | 34 |
ige binding | 34 |
colon cancer | 34 |
twice daily | 34 |
human macrophages | 34 |
protective effects | 34 |
mean values | 34 |
apache ii | 34 |
major cause | 34 |
using recombinant | 34 |
asthma severity | 34 |
medical history | 34 |
standard curve | 34 |
may influence | 34 |
per year | 34 |
hemorrhagic fever | 34 |
inclusion bodies | 34 |
four times | 34 |
adult patients | 34 |
may reflect | 34 |
standard deviations | 34 |
antibodies specific | 34 |
ev subpopulations | 34 |
fetal brain | 34 |
therapeutic agents | 34 |
insect cells | 34 |
wide variety | 34 |
single cell | 34 |
thrombin generation | 34 |
five patients | 34 |
enzyme linked | 34 |
early stages | 34 |
mitochondrial membrane | 34 |
surveillance system | 34 |
left ventricular | 34 |
studies using | 34 |
results may | 34 |
small intestine | 34 |
plasma evs | 34 |
cytotoxic effect | 34 |
clinical manifestations | 34 |
allergic inflammation | 34 |
important roles | 34 |
follicular fluid | 34 |
antibody test | 34 |
cardiac output | 34 |
antibodies directed | 34 |
asthma patients | 34 |
plasmid dna | 34 |
previously published | 33 |
herpes simplex | 33 |
cytokine expression | 33 |
glucose levels | 33 |
will provide | 33 |
elisa showed | 33 |
kindly provided | 33 |
fast set | 33 |
cancer stem | 33 |
mice treated | 33 |
exosomes derived | 33 |
th day | 33 |
using anti | 33 |
specific antisera | 33 |
purified recombinant | 33 |
elisa format | 33 |
therapeutic strategies | 33 |
immune status | 33 |
economic losses | 33 |
antiviral activity | 33 |
clinical outcome | 33 |
high fat | 33 |
bactericidal activity | 33 |
first case | 33 |
expression analysis | 33 |
developed using | 33 |
human coronaviruses | 33 |
coronary artery | 33 |
model system | 33 |
sodium dodecyl | 33 |
scanning electron | 33 |
hepatocellular carcinoma | 33 |
bacterial growth | 33 |
flow cytometer | 33 |
facs analysis | 33 |
assay kit | 33 |
igg detection | 33 |
mice compared | 33 |
fold change | 33 |
treatment period | 33 |
negative bacteria | 33 |
clinical features | 33 |
analysis indicated | 33 |
complete blood | 33 |
proinflammatory cytokine | 33 |
open reading | 33 |
spleen cells | 33 |
replacement therapy | 33 |
roc curve | 33 |
mcg ml | 33 |
among patients | 33 |
blood levels | 33 |
two distinct | 33 |
seasonal allergic | 33 |
ct scan | 33 |
mean value | 33 |
mouse serum | 33 |
promoter region | 32 |
two major | 32 |
dna methylation | 32 |
genome sequence | 32 |
vitro studies | 32 |
geometric mean | 32 |
sensitive detection | 32 |
mediated immune | 32 |
milk samples | 32 |
protein expressed | 32 |
rotavirus infection | 32 |
oral administration | 32 |
definitive diagnosis | 32 |
young children | 32 |
largely unknown | 32 |
pollen season | 32 |
coating antigen | 32 |
luciferase reporter | 32 |
many different | 32 |
cell carcinoma | 32 |
blood serum | 32 |
susceptibility testing | 32 |
syndrome virus | 32 |
immunocompetent mice | 32 |
egg white | 32 |
epidemic diarrhoea | 32 |
washed times | 32 |
rna extraction | 32 |
consecutive days | 32 |
clinical characteristics | 32 |
science foundation | 32 |
mtt assay | 32 |
coronavirus infections | 32 |
done using | 32 |
serum igg | 32 |
tumour growth | 32 |
purified protein | 32 |
time consuming | 32 |
pathway analysis | 32 |
diagnostic value | 32 |
female mice | 32 |
highly expressed | 32 |
heavy chain | 32 |
matrix metalloproteinases | 32 |
body fluids | 32 |
mice showed | 32 |
biological samples | 32 |
inhibition assay | 32 |
passive immunotherapy | 32 |
emergency department | 32 |
tumour microenvironment | 32 |
values obtained | 32 |
nucleotide sequences | 32 |
clinical efficacy | 32 |
using serum | 32 |
disk diffusion | 32 |
medical research | 32 |
protein cargo | 32 |
early pregnancy | 31 |
plasminogen activator | 31 |
dna vaccines | 31 |
asthma exacerbation | 31 |
performance liquid | 31 |
weeks later | 31 |
immunoblot analysis | 31 |
mice infected | 31 |
teaching hospital | 31 |
male wistar | 31 |
treated rats | 31 |
nuclear translocation | 31 |
gene encoding | 31 |
weeks post | 31 |
virus infected | 31 |
ad libitum | 31 |
inflammatory activity | 31 |
general anesthesia | 31 |
distilled water | 31 |
least two | 31 |
patients diagnosed | 31 |
cardiovascular diseases | 31 |
novel therapeutic | 31 |
vaccinia virus | 31 |
high doses | 31 |
mycobacterium avium | 31 |
small evs | 31 |
nucleotide sequence | 31 |
healthy adult | 31 |
synthetic peptides | 31 |
clinical response | 31 |
hiv infection | 31 |
sera collected | 31 |
clavulanic acid | 31 |
odds ratio | 31 |
microtiter plates | 31 |
following treatment | 31 |
host cell | 31 |
clinical study | 31 |
specific monoclonal | 31 |
treated group | 31 |
dust mites | 31 |
resistant isolates | 31 |
early phase | 31 |
acute myocardial | 31 |
clinical presentation | 31 |
human disease | 31 |
severe sepsis | 31 |
human respiratory | 31 |
blood collection | 31 |
results suggested | 31 |
fetal bovine | 31 |
molecular mass | 31 |
hours later | 31 |
infectious virus | 30 |
hemagglutination inhibition | 30 |
signalling pathway | 30 |
protease inhibitor | 30 |
age years | 30 |
target cell | 30 |
human metapneumovirus | 30 |
protein markers | 30 |
research center | 30 |
per patient | 30 |
kidney disease | 30 |
diarrhoea virus | 30 |
post onset | 30 |
pulmonary function | 30 |
new zealand | 30 |
cytokines il | 30 |
granulosa cells | 30 |
map kinase | 30 |
less likely | 30 |
mice lacking | 30 |
latex agglutination | 30 |
terminal domain | 30 |
serum creatinine | 30 |
symptom score | 30 |
provide evidence | 30 |
nasal swabs | 30 |
cells infected | 30 |
positive patients | 30 |
patient samples | 30 |
linear range | 30 |
type specific | 30 |
cell number | 30 |
transforming growth | 30 |
showed significantly | 30 |
two days | 30 |
infections caused | 30 |
whole virus | 30 |
stress response | 30 |
type iii | 30 |
serologic assays | 30 |
genbank accession | 30 |
resonance imaging | 30 |
fasciola hepatica | 30 |
human endometrial | 30 |
tomato leaf | 30 |
study provides | 30 |
investigated using | 30 |
recombinant baculovirus | 30 |
also shown | 30 |
national university | 30 |
first week | 30 |
challenge test | 30 |
viral protein | 30 |
antioxidant status | 30 |
pedv infection | 30 |
effector cells | 30 |
viral loads | 30 |
therapeutic target | 30 |
acm device | 30 |
enzyme activities | 30 |
within normal | 30 |
currently used | 30 |
included patients | 30 |
proteins involved | 30 |
natural infection | 30 |
nkt cell | 30 |
curve analysis | 30 |
posted july | 30 |
seven days | 30 |
venous thrombosis | 30 |
four groups | 29 |
also studied | 29 |
th cytokines | 29 |
secondary antibodies | 29 |
maternal plasma | 29 |
blood sample | 29 |
per group | 29 |
dna binding | 29 |
platelet counts | 29 |
clinical history | 29 |
eoc cells | 29 |
clinical relevance | 29 |
diagnostic tools | 29 |
inflammatory properties | 29 |
complement system | 29 |
confirmed cases | 29 |
first days | 29 |
good agreement | 29 |
ha gene | 29 |
many studies | 29 |
data collection | 29 |
thermal injury | 29 |
roc analysis | 29 |
cytokine secretion | 29 |
vaccine candidates | 29 |
ev production | 29 |
indirect immunofluorescence | 29 |
sialic acid | 29 |
plaque assay | 29 |
cell epitopes | 29 |
platelet function | 29 |
samples taken | 29 |
surface marker | 29 |
bile acids | 29 |
elisa plate | 29 |
body condition | 29 |
molecular characterization | 29 |
antigenic sites | 29 |
patients admitted | 29 |
medium supplemented | 29 |
southern china | 29 |
white matter | 29 |
drug allergy | 29 |
also detected | 29 |
lavage fluid | 29 |
antigen detection | 29 |
vitro activity | 29 |
diagnostic laboratory | 29 |
pulmonary fibrosis | 29 |
square test | 29 |
vascular resistance | 29 |
synovial fluid | 29 |
one case | 29 |
antibody binding | 29 |
also investigated | 29 |
pcr testing | 29 |
regression model | 29 |
ra patients | 29 |
clinical laboratory | 29 |
human cd | 29 |
normal pregnancy | 29 |
culture conditions | 29 |
bacterial translocation | 29 |
soft tissue | 29 |
samples showed | 29 |
plasma glucose | 29 |
berne virus | 29 |
flow rate | 29 |
separation capillary | 29 |
confidence intervals | 29 |
recent study | 29 |
study groups | 29 |
plaque reduction | 29 |
gp i | 28 |
stool samples | 28 |
allergic symptoms | 28 |
decidual cells | 28 |
patienten mit | 28 |
infected cell | 28 |
inflammatory disease | 28 |
clinical setting | 28 |
control dogs | 28 |
viral genome | 28 |
two types | 28 |
brain injury | 28 |
different species | 28 |
ischemia reperfusion | 28 |
isothermal amplification | 28 |
tumor suppressor | 28 |
evidence suggests | 28 |
markers cd | 28 |
pcr method | 28 |
bacterial cells | 28 |
research council | 28 |
liver disease | 28 |
environmental factors | 28 |
dose response | 28 |
epidermal growth | 28 |
ml kg | 28 |
human endometrium | 28 |
clinical applications | 28 |
probably due | 28 |
study using | 28 |
rna sequencing | 28 |
mosaic virus | 28 |
matched controls | 28 |
positive controls | 28 |
cell derived | 28 |
calf serum | 28 |
brain barrier | 28 |
samples tested | 28 |
biological materials | 28 |
ml vs | 28 |
neutralization assays | 28 |
study revealed | 28 |
genetically modified | 28 |
infection control | 28 |
arterial pressure | 28 |
light scattering | 28 |
tumour cell | 28 |
hela cells | 28 |
enzymatic activity | 28 |
operating characteristic | 28 |
igm elisa | 28 |
significant increases | 28 |
commercial kit | 28 |
significant change | 28 |
different stages | 28 |
among women | 28 |
cells express | 28 |
receiver operating | 28 |
dynamic range | 28 |
showed similar | 28 |
using primers | 28 |
anaphylactic reaction | 28 |
myeloid cells | 28 |
virus detection | 28 |
significantly enhanced | 28 |
crp levels | 28 |
knockout mice | 28 |
like illness | 28 |
serum concentration | 28 |
serum il | 28 |
secretory phase | 28 |
fetal plasma | 28 |
human infection | 28 |
mean ae | 27 |
vitro experiments | 27 |
inflammatory conditions | 27 |
hek cells | 27 |
cytokine il | 27 |
new insights | 27 |
cellular uptake | 27 |
chart review | 27 |
thrombus formation | 27 |
recent advances | 27 |
also present | 27 |
contact dermatitis | 27 |
classical swine | 27 |
treg cells | 27 |
phosphate buffer | 27 |
samples using | 27 |
potential biomarkers | 27 |
inflammatory process | 27 |
findings may | 27 |
gastrointestinal disease | 27 |
mouse colonies | 27 |
mic values | 27 |
antibiotic resistance | 27 |
beneficial effect | 27 |
human placenta | 27 |
pollen allergy | 27 |
specific elisa | 27 |
lung disease | 27 |
days pos | 27 |
six patients | 27 |
vivo studies | 27 |
biological fluids | 27 |
high density | 27 |
among children | 27 |
fever virus | 27 |
proteolytic activity | 27 |
time period | 27 |
normal dogs | 27 |
cells mm | 27 |
roc curves | 27 |
recently reported | 27 |
cervical cancer | 27 |
fold lower | 27 |
infected vero | 27 |
activation markers | 27 |
therapeutic approach | 27 |
liver injury | 27 |
antigen test | 27 |
affected dogs | 27 |
expressed genes | 27 |
repeated measures | 27 |
therapeutic targets | 27 |
point mutation | 27 |
control measures | 27 |
leydig cells | 27 |
clinical improvement | 27 |
method using | 27 |
aureus strains | 27 |
days prior | 27 |
assays using | 27 |
medical university | 27 |
culture system | 27 |
mouse strains | 27 |
adjuvanted vaccine | 27 |
antigen processing | 27 |
coat protein | 27 |
tandem mass | 27 |
mortality rates | 27 |
life technologies | 27 |
general hospital | 27 |
whole genome | 27 |
villous explants | 27 |
per ml | 27 |
aged years | 27 |
less sensitive | 27 |
detecting antibodies | 27 |
study demonstrated | 27 |
studies show | 27 |
circulating evs | 27 |
pancreatic cancer | 27 |
drinking water | 27 |
may suggest | 27 |
reverse genetics | 27 |
gastrointestinal tract | 27 |
play important | 27 |
small molecules | 27 |
retrospective analysis | 27 |
small animal | 27 |
sera obtained | 27 |
results revealed | 27 |
mirna expression | 27 |
diluted serum | 27 |
acquired pneumonia | 27 |
los angeles | 27 |
acid sequences | 27 |
serologic testing | 27 |
trauma patients | 27 |
elisa methods | 27 |
survival time | 27 |
log cfu | 26 |
therapeutic approaches | 26 |
allergic disease | 26 |
marker vaccines | 26 |
previous reports | 26 |
prothrombin time | 26 |
age range | 26 |
fowl adenovirus | 26 |
virus particles | 26 |
test using | 26 |
short term | 26 |
serum total | 26 |
higher concentrations | 26 |
viral disease | 26 |
plasma volume | 26 |
clotting time | 26 |
tlr ligands | 26 |
erk activation | 26 |
using monoclonal | 26 |
specific detection | 26 |
antiviral treatment | 26 |
powerful tool | 26 |
nasal washings | 26 |
cells ml | 26 |
maternal age | 26 |
antimicrobial susceptibility | 26 |
delivery system | 26 |
cytokine response | 26 |
old man | 26 |
membrane potential | 26 |
limited number | 26 |
may indicate | 26 |
total antioxidant | 26 |
fetal sheep | 26 |
direct elisa | 26 |
newcastle disease | 26 |
normal controls | 26 |
african green | 26 |
cytokine release | 26 |
ige mediated | 26 |
infection status | 26 |
avian infectious | 26 |
endothelial growth | 26 |
lipid rafts | 26 |
mice received | 26 |
steady state | 26 |
also reduced | 26 |
additional studies | 26 |
endemic areas | 26 |
candidate genes | 26 |
kg body | 26 |
blood vessels | 26 |
dendritic cell | 26 |
north american | 26 |
binding activity | 26 |
companion animals | 26 |
inflammatory effect | 26 |
inflammatory effects | 26 |
years ago | 26 |
ae lg | 26 |
medication use | 26 |
one day | 26 |
respiratory pathogens | 26 |
clinical significance | 26 |
safety profile | 26 |
plasma concentration | 26 |
quantitative pcr | 26 |
major allergen | 26 |
forming units | 26 |
large numbers | 26 |
mesenteric lymph | 26 |
one sample | 26 |
animal studies | 26 |
intrauterine growth | 26 |
microtiter plate | 26 |
mediated immunity | 26 |
many countries | 26 |
lesser extent | 26 |
mesenchymal stromal | 26 |
large amounts | 26 |
equine sera | 26 |
regulatory role | 26 |
exhaled breath | 26 |
expression patterns | 26 |
acute lung | 26 |
noise ratio | 26 |
using either | 26 |
drug administration | 26 |
respiratory diseases | 26 |
czech republic | 26 |
celiac disease | 26 |
patient groups | 26 |
reactive antibodies | 26 |
trend towards | 25 |
gene silencing | 25 |
passive immunity | 25 |
protease inhibitors | 25 |
fetal weight | 25 |
western immunoblot | 25 |
biomedical research | 25 |
transfected cells | 25 |
factor receptor | 25 |
generation sequencing | 25 |
ige reactivity | 25 |
jugular vein | 25 |
stimulating factor | 25 |
inhaled corticosteroids | 25 |
ang ii | 25 |
healthy cats | 25 |
allergen immunotherapy | 25 |
phosphate buffered | 25 |
showed positive | 25 |
virus type | 25 |
molecular markers | 25 |
group received | 25 |
school children | 25 |
post infection | 25 |
recombinant antigen | 25 |
pcr results | 25 |
resistance genes | 25 |
human parechovirus | 25 |
barrier function | 25 |
fully understood | 25 |
vein endothelial | 25 |
methods used | 25 |
eosinophil count | 25 |
nasal symptoms | 25 |
surface protein | 25 |
antimicrobial agents | 25 |
clinically significant | 25 |
suspect results | 25 |
icu patients | 25 |
normal pregnancies | 25 |
convalescent serum | 25 |
density lipoprotein | 25 |
membrane fusion | 25 |
systemic inflammation | 25 |
humoral response | 25 |
sectional study | 25 |
inhibitory concentration | 25 |
onset preeclampsia | 25 |
mean serum | 25 |
cancer progression | 25 |
protein bands | 25 |
increased il | 25 |
epitope mapping | 25 |
saudi arabia | 25 |
antibiotic use | 25 |
elderly patients | 25 |
cigarette smoke | 25 |
molecular mechanism | 25 |
lps stimulation | 25 |
health problem | 25 |
resistant staphylococcus | 25 |
also measured | 25 |
strong positive | 25 |
miu ml | 25 |
antioxidant capacity | 25 |
previous work | 25 |
therapeutic effect | 25 |
dengue virus | 25 |
health sciences | 25 |
increasing concentrations | 25 |
antiviral drugs | 25 |
protective role | 25 |
observation period | 25 |
three weeks | 25 |
four weeks | 25 |
cellular processes | 25 |
next generation | 25 |
infectious peritonitis | 25 |
nucleotide polymorphisms | 25 |
experimental animals | 25 |
two months | 25 |
lymphocyte count | 25 |
patch test | 25 |
groups according | 25 |
cd positive | 25 |
kg bw | 25 |
late gestation | 25 |
protein production | 25 |
observational study | 25 |
ab elisa | 25 |
systematic review | 25 |
human myometrial | 25 |
reporter gene | 25 |
patients may | 25 |
pearson correlation | 25 |
vitro model | 25 |
young adults | 25 |
chi square | 25 |
au ml | 25 |
old boy | 25 |
cancer therapy | 25 |
adult mice | 25 |
cytokine profile | 25 |
porcine circovirus | 25 |
cells cultured | 25 |
remained unchanged | 25 |
patients died | 25 |
also positive | 25 |
adult horses | 25 |
degradation products | 25 |
high concentration | 25 |
minute virus | 25 |
anaplasma phagocytophilum | 25 |
active site | 25 |
mammalian cells | 25 |
urea dissociation | 24 |
breda virus | 24 |
immune function | 24 |
developed elisa | 24 |
equal volume | 24 |
organ injury | 24 |
screening test | 24 |
clinically ill | 24 |
two dogs | 24 |
three months | 24 |
different methods | 24 |
asthmatic children | 24 |
trophoblast cell | 24 |
ev numbers | 24 |
cells play | 24 |
direct detection | 24 |
microvascular endothelial | 24 |
graphpad prism | 24 |
study also | 24 |
embryo transfer | 24 |
lipid metabolism | 24 |
might also | 24 |
carcinoma cells | 24 |
posted june | 24 |
rrna gene | 24 |
correlated well | 24 |
mrna level | 24 |
cells also | 24 |
high molecular | 24 |
immune complexes | 24 |
mitral valve | 24 |
mdck pf | 24 |
patients using | 24 |
influenza season | 24 |
surface receptors | 24 |
arteritis virus | 24 |
stress conditions | 24 |
common elisa | 24 |
incubated overnight | 24 |
nitrocellulose membrane | 24 |
intranasal administration | 24 |
exchange chromatography | 24 |
patients underwent | 24 |
chronic obstructive | 24 |
cytotoxic effects | 24 |
cell numbers | 24 |
particles ml | 24 |
pediatric patients | 24 |
concentration range | 24 |
two doses | 24 |
cell index | 24 |
obtained results | 24 |
controlled trial | 24 |
membrane vesicles | 24 |
remains unknown | 24 |
idexx elisa | 24 |
south africa | 24 |
copy number | 24 |
bacterial pathogens | 24 |
vero cell | 24 |
clinical outcomes | 24 |
provide new | 24 |
induced cytokine | 24 |
two times | 24 |
obstetrics gynecology | 24 |
reference range | 24 |
studied using | 24 |
diffusion method | 24 |
encephalomyelitis virus | 24 |
glioma cells | 24 |
allergic airway | 24 |
magnetic beads | 24 |
equine arteritis | 24 |
positive blood | 24 |
levels may | 24 |
reading frame | 24 |
may therefore | 24 |
five different | 24 |
tissue sections | 24 |
positive cases | 24 |
elevated serum | 24 |
total body | 24 |
cell biology | 24 |
simplex virus | 24 |
pandemic vaccine | 24 |
persistent infection | 24 |
decreased expression | 24 |
asthma medication | 24 |
swine serum | 24 |
listeria monocytogenes | 24 |
bicarbonate buffer | 24 |
among different | 24 |
purified virus | 24 |
conserved among | 24 |
rna virus | 24 |
glucose uptake | 24 |
lps challenge | 24 |
laboratory diagnosis | 24 |
inflammatory reaction | 24 |
dna polymerase | 24 |
patients infected | 24 |
induced il | 24 |
adoptive transfer | 24 |
different times | 24 |
national institutes | 24 |
severe cases | 24 |
inflammatory reactions | 24 |
ae sd | 24 |
sera samples | 24 |
group consisted | 24 |
mean od | 24 |
specific igm | 24 |
inhibitory activity | 24 |
embryonated chicken | 24 |
san diego | 24 |
severe allergic | 24 |
ligand binding | 24 |
cross reactivity | 24 |
cell interactions | 24 |
computed tomography | 24 |
azelastine nasal | 24 |
higher rate | 23 |
great potential | 23 |
many patients | 23 |
fruit bats | 23 |
newborn offspring | 23 |
elevating virus | 23 |
antibody concentrations | 23 |
evs may | 23 |
assess whether | 23 |
induced activation | 23 |
baseline values | 23 |
peritoneal cavity | 23 |
gene sequence | 23 |
incubation period | 23 |
staphylococcal enterotoxin | 23 |
energy metabolism | 23 |
obstructive pulmonary | 23 |
virus shedding | 23 |
nasal polyps | 23 |
cycle arrest | 23 |
ae ae | 23 |
serum level | 23 |
bovine viral | 23 |
biological activities | 23 |
test samples | 23 |
low concentration | 23 |
also examined | 23 |
virus titers | 23 |
immunodeficiency virus | 23 |
toxoplasma gondii | 23 |
body temperature | 23 |
cultured human | 23 |
fetal lung | 23 |
canine parvovirus | 23 |
diseases including | 23 |
high expression | 23 |
gnrh ii | 23 |
recently identified | 23 |
school closure | 23 |
complement activation | 23 |
binding capacity | 23 |
hr post | 23 |
immunohistochemical analysis | 23 |
scoring system | 23 |
dependent increase | 23 |
paraffin embedded | 23 |
negative sepsis | 23 |
polyethylene glycol | 23 |
cd high | 23 |
two independent | 23 |
rna polymerase | 23 |
urgent need | 23 |
feline infectious | 23 |
quantitative analysis | 23 |
examined using | 23 |
nude mice | 23 |
laboratory animals | 23 |
postoperative day | 23 |
five times | 23 |
squamous cell | 23 |
nasal discharge | 23 |
allowed us | 23 |
shear stress | 23 |
every hours | 23 |
highly immunogenic | 23 |
chicken egg | 23 |
important factor | 23 |
specific pathogen | 23 |
sepsis syndrome | 23 |
results provide | 23 |
extracted using | 23 |
cells derived | 23 |
actin cytoskeleton | 23 |
first line | 23 |
alveolar macrophages | 23 |
least days | 23 |
igg igm | 23 |
within one | 23 |
neurodegenerative diseases | 23 |
found positive | 23 |
one group | 23 |
last decade | 23 |
eight patients | 23 |
blood lymphocytes | 23 |
marrow derived | 23 |
laboratory findings | 23 |
many diseases | 23 |
fluid samples | 23 |
thromboplastin time | 23 |
matrix metalloproteinase | 23 |
genetic diversity | 23 |
using spss | 23 |
protein assay | 23 |
ige antibodies | 23 |
purified sars | 23 |
acid changes | 23 |
antithrombin iii | 23 |
vein thrombosis | 23 |
two strains | 23 |
mean arterial | 23 |
one month | 23 |
hours following | 23 |
nasal mucosa | 23 |
exosomes isolated | 23 |
bovine coronavirus | 23 |
natural history | 23 |
placental tissue | 23 |
recently demonstrated | 23 |
nasal washes | 23 |
cells transfected | 23 |
mm edta | 23 |
immunodeficient mice | 23 |
factor alpha | 23 |
rhinitis symptoms | 23 |
pedv antibodies | 23 |
virus vaccine | 23 |
reference ranges | 23 |
liver failure | 23 |
patients aged | 23 |
high yield | 23 |
cell transplantation | 23 |
sequence identity | 23 |
antibacterial activity | 23 |
viral pathogens | 23 |
consecutive patients | 23 |
dairy products | 23 |
st cells | 23 |
spike polypeptide | 23 |
aea levels | 23 |
lps injection | 23 |
hearing loss | 23 |
coli bl | 23 |
avium subsp | 23 |
will allow | 23 |
antimicrobial therapy | 23 |
patients developed | 23 |
showed increased | 23 |
assay sensitivity | 23 |
helicobacter pylori | 22 |
technical assistance | 22 |
molecular epidemiology | 22 |
analysis demonstrated | 22 |
study aims | 22 |
mhc i | 22 |
vaccine candidate | 22 |
reproductive tract | 22 |
persistent pulmonary | 22 |
agar plates | 22 |
related viruses | 22 |
detection method | 22 |
coagulation parameters | 22 |
previously identified | 22 |
expressed proteins | 22 |
associated proteins | 22 |
single ev | 22 |
blocking solution | 22 |
laboratory data | 22 |
derived ev | 22 |
also confirmed | 22 |
active metabolite | 22 |
reduced expression | 22 |
neutralizing activity | 22 |
conventional elisa | 22 |
ae ng | 22 |
derived macrophages | 22 |
specific antigen | 22 |
pedv specific | 22 |
intraperitoneal injection | 22 |
versus ae | 22 |
transplant recipients | 22 |
length polymorphism | 22 |
recently described | 22 |
checkerboard titration | 22 |
monoclonal anti | 22 |
solid phase | 22 |
image analysis | 22 |
agarose gel | 22 |
diagnostic laboratories | 22 |
developing countries | 22 |
sensor surface | 22 |
biomarker analyzer | 22 |
monocytes macrophages | 22 |
constitutively expressed | 22 |
fluorescence intensity | 22 |
antigen specific | 22 |
south korea | 22 |
coagulation factors | 22 |
patient serum | 22 |
antioxidant activity | 22 |
foxn nu | 22 |
highly correlated | 22 |
reuse allowed | 22 |
soluble non | 22 |
elisa antibody | 22 |
microplate reader | 22 |
also seen | 22 |
surface antigen | 22 |
disease diagnosis | 22 |
rna isolation | 22 |
i ifn | 22 |
medium containing | 22 |
liver tissue | 22 |
well understood | 22 |
mice using | 22 |
vaccine strains | 22 |
test result | 22 |
substrate solution | 22 |
experimental conditions | 22 |
cytotoxic activity | 22 |
also able | 22 |
clinical microbiology | 22 |
dodecyl sulfate | 22 |
days following | 22 |
cd foxp | 22 |
studies demonstrated | 22 |
calibration curve | 22 |
mice immunized | 22 |
iga antibodies | 22 |
positive rate | 22 |
test serum | 22 |
differ significantly | 22 |
statistically significantly | 22 |
much lower | 22 |
allowed without | 22 |
ev preparations | 22 |
blood sampling | 22 |
fluorescent protein | 22 |
endothelial dysfunction | 22 |
small rnas | 22 |
inactivated vaccine | 22 |
xanthine oxidase | 22 |
mean duration | 22 |
fluorescent antibody | 22 |
lactation period | 22 |
patient developed | 22 |
ev protein | 22 |
circulating antibodies | 22 |
high resolution | 22 |
inflammatory markers | 22 |
normal values | 22 |
electron microscope | 22 |
cd ratio | 22 |
blood coagulation | 22 |
household contacts | 22 |
humoral immunity | 22 |
serum tt | 22 |
der patienten | 22 |
study indicates | 22 |
imi cis | 22 |
patient presented | 22 |
igm antibody | 22 |
based methods | 22 |
hospital stay | 22 |
normal levels | 22 |
tree pollen | 22 |
strongly suggest | 22 |
data provide | 22 |
blot assay | 22 |
liver function | 22 |
active form | 22 |
virus disease | 22 |
na genes | 22 |
without permission | 22 |
marked increase | 22 |
total cholesterol | 22 |
cell membranes | 22 |
fold serial | 22 |
left atrial | 22 |
bartonella spp | 22 |
cells grown | 22 |
sequence data | 22 |
target antigen | 22 |
normal limits | 22 |
ad patients | 22 |
alveolar epithelial | 22 |
lamina propria | 22 |
kg iv | 21 |
collagen type | 21 |
insulin levels | 21 |
intravenous administration | 21 |
group showed | 21 |
rank test | 21 |
study suggest | 21 |
macrophage activation | 21 |
corona diferencial | 21 |
preliminary study | 21 |
primary outcome | 21 |
differed significantly | 21 |
isolation rate | 21 |
respiratory failure | 21 |
household transmission | 21 |
despite enhanced | 21 |
ev proteins | 21 |
low prevalence | 21 |
ev surface | 21 |
ingezim corona | 21 |
protective immune | 21 |
healthy women | 21 |
regression models | 21 |
expressing cd | 21 |
tumour progression | 21 |
signal peptide | 21 |
immune regulation | 21 |
sublingual immunotherapy | 21 |
secondary bacterial | 21 |
throughout pregnancy | 21 |
using real | 21 |
acid use | 21 |
ii score | 21 |
test performance | 21 |
gene transcription | 21 |
cell degranulation | 21 |
hi test | 21 |
human population | 21 |
biological function | 21 |
antigenic drift | 21 |
dna sequence | 21 |
health research | 21 |
results support | 21 |
specific anti | 21 |
whole body | 21 |
present data | 21 |
internal genes | 21 |
selective cox | 21 |
different groups | 21 |
experimental group | 21 |
uterine emg | 21 |
adverse event | 21 |
neutralising mabs | 21 |
cells stimulated | 21 |
cell mediated | 21 |
antibiotic susceptibility | 21 |
neuronal cells | 21 |
complement fixation | 21 |
pregnant mice | 21 |
higher expression | 21 |
female balb | 21 |
human health | 21 |
surface proteins | 21 |
transduction pathways | 21 |
healthy horses | 21 |
tgev strain | 21 |
will also | 21 |
mechanical ventilation | 21 |
protein kinases | 21 |
blood results | 21 |
time reverse | 21 |
well defined | 21 |
vitro stimulation | 21 |
cell counts | 21 |
cecal ligation | 21 |
similar pattern | 21 |
chronic kidney | 21 |
slightly lower | 21 |
rt pcr | 21 |
therapeutic effects | 21 |
regenerative medicine | 21 |
per week | 21 |
following incubation | 21 |
inhibition elisa | 21 |
sendai virus | 21 |
potential target | 21 |
microarray analysis | 21 |
capillary blood | 21 |
slightly higher | 21 |
using quantitative | 21 |
vice versa | 21 |
polycystic ovary | 21 |
disease caused | 21 |
soluble fibrin | 21 |
human seasonal | 21 |
tests showed | 21 |
patients presented | 21 |
first day | 21 |
virus neutralizing | 21 |
high frequency | 21 |
molecular techniques | 21 |